An unusual Burkholderia gladioli double chain-initiating nonribosomal peptide synthetase assembles ‘fungal’ icosalide antibiotics by Jenner, Matthew et al.
Chemical
Science
EDGE ARTICLE
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
5 
A
pr
il 
20
19
. D
ow
nl
oa
de
d 
on
 5
/1
3/
20
19
 2
:1
2:
39
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View JournalAn unusual BurkaDepartment of Chemistry, University of Wa
challis@warwick.ac.uk
bWarwick Integrative Synthetic Biology Cen
7AL, UK
cBiomedicine Discovery Institute, Departmen
Monash University, Victoria 3800, Australia
dOrganisms and Environment Division,
University, Main Building, Park Place, Card
eWellcome Trust Sanger Institute, Wellco
Cambridge CB10 1SA, UK
fDepartment of Chemistry and Biochemi
Greensboro, Greensboro, NC 27402, USA
gMycosynthetix, 4905 Pine Cone Drive, Durh
† Electronic supplementary informa
10.1039/c8sc04897e
‡ These authors contributed equally.
Cite this: DOI: 10.1039/c8sc04897e
All publication charges for this article
have been paid for by the Royal Society
of Chemistry
Received 2nd November 2018
Accepted 22nd April 2019
DOI: 10.1039/c8sc04897e
rsc.li/chemical-science
This journal is © The Royal Society ofholderia gladioli double chain-
initiating nonribosomal peptide synthetase
assembles ‘fungal’ icosalide antibiotics†
Matthew Jenner, ‡ab Xinyun Jian,‡a Yousef Dashti, a Joleen Masschelein, a
Christian Hobson,a Douglas M. Roberts,a Cerith Jones, d Simon Harris, e
Julian Parkhill, e Huzefa A. Raja, f Nicholas H. Oberlies, f Cedric J. Pearce,g
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Burkholderia is a multi-talented genus of Gram-negative bacteria, which in recent years has become
increasingly recognised as a promising source of bioactive natural products. Metabolite proﬁling of
Burkholderia gladioli BCC0238 showed that it produces the asymmetric lipopeptidiolide antibiotic
icosalide A1, originally isolated from a fungus. Comparative bioinformatics analysis of several genome-
sequenced B. gladioli isolates identiﬁed a gene encoding a nonribosomal peptide synthase (NRPS) with
an unusual architecture that was predicted to be responsible for icosalide biosynthesis. Inactivation of
this gene in B. gladioli BCC0238 abolished icosalide production. PCR analysis and sequencing of total
DNA from the original fungal icosalide A1 producer revealed it has a B. gladioli strain associated with it
that harbours an NRPS with an identical architecture to that responsible for icosalide A1 assembly in B.
gladioli BCC0238. Sequence analysis of the icosalide NRPS indicated that it contains two chain-initiating
condensation (CI) domains. One of these is appended to the N-terminus of module 1 – a common
architecture for NRPSs involved in lipopeptide assembly. The other is embedded in module 3,
immediately downstream of a putative chain-elongating condensation domain. Analysis of the reactions
catalysed by a tridomain construct from module 3 of the NRPS using intact protein mass spectrometry
showed that the embedded CI domain initiates assembly of a second lipopeptide chain, providing key
insights into the mechanism for asymmetric diolide assembly.Introduction
Bacteria belonging to the Burkholderia genus thrive in various
ecological niches, ranging from the plant rhizosphere to the
human lung, and play critical roles in ecological interactions
oen through the secretion of specialised metabolites.1,2 Therwick, Coventry CV4 7AL, UK. E-mail: g.l.
tre, University of Warwick, Coventry CV4
t of Biochemistry and Molecular Biology,
Cardiﬀ School of Biosciences, Cardiﬀ
iﬀ CF10 3AT, UK
me Trust Genome Campus, Hinxton,
stry, University, of North Carolina at
am, North Carolina, 27707, USA
tion (ESI) available. See DOI:
Chemistry 2019metabolic arsenal of these bacteria is employed to eliminate
other bacterial competitors and suppress plant pathogenic
fungi and nematodes. In recent years various Burkholderia
species have been shown to produce numerous specialised
metabolites, many of which are assembled by polyketide syn-
thases (PKSs) and nonribosomal peptide synthetases (NRPSs)
biosynthetic assembly lines.3 Notable examples include: the
respiratory toxin bongkrekic acid;4 anti-proliferative agents
such as thailanstatin and spliceostatin;5,6 and the antibiotics
enacyloxin IIa and gladiolin.7,8
Burkholderia participate in both antagonistic andmutualistic
interactions with fungi. Much of the antagonistic behaviour can
be attributed to an array of antifungal compounds secreted by
many Burkholderia species.9–12 However, it has also been re-
ported that Burkholderia strains have benecial eﬀects on fungi,
suggestive of symbiotic, or at least mutualistic interactions.13–15
The exemplar study of this relationship is the symbiotic pairing
of Burkholderia rhizoxinica (since reclassied as Para-
burkholderia rhizoxinica) and the rice seedling blight pathogen
Rhizopus microspores. B. rhizoxinica was identied as the
producer of the antimitotic macrolide rhizoxin, the causative
agent of rice seedling blight.10,16Chem. Sci.
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View Article OnlineIn a preliminary communication, we disclosed that Bur-
kholderia gladioli isolates from cystic brosis (CF) patients
produce icosalide A1 (1),17 a lipopeptidiolide antibiotic origi-
nally isolated from a fungus.18 We also showed that a non-
ribosomal peptide synthetase (NRPS) with an unusual
architecture is responsible for icosalide A1 assembly.17 Subse-
quently, Hertweck and co-workers reported that a B. gladioli
endosymbiont of a beetle, along with several other Burkholderia
species from diverse sources, also produce icosalide A1 and
showed that an NRPS with the same unusual architecture as
that identied in the CF isolates is responsible for its biosyn-
thesis.19 Here we provide a full account of our work and show
that a B. gladioli strain containing the icosalide A1 NRPS is
associated with the originally reported fungal producer. More-
over, we demonstrate that a chain-initiating condensation (CI)
domain embedded in the middle of the icosalide A1 NRPS
selectively N-acylates a serinyl thioester covalently attached to
the downstream peptidyl carrier protein (PCP) domain with
a (3R)-3-hydroxydecanoyl panthetheine thioester, providing
a mechanistic rationale for asymmetric lipopeptidiolide
formation.
Results and discussion
We recently reported the discovery of gladiolin, a novel mac-
rolide antibiotic with promising activity against Mycobacterium
tuberculosis (MIC ¼ 0.4 mg mL1) and low mammalian cell
cytotoxicity, from B. gladioli BCC0238 (LMG-P26202).7 In the
course of investigations of other specialised metabolites
produced by this CF clinical isolate using UHPLC-ESI-Q-TOF-
MS, compounds with the molecular formulae C36H64N4O10
and C34H60N4O10 were observed (Fig S1 and S2†). These
molecular formulae correspond to a set of three structurally-
related lipopeptidiolides, known as icosalides A1 (1), A2 (2)
and B (3), reported to be produced by fungi18 (Fig. 1A).
The icosalides possess similar 20-membered lip-
opeptidiolide structures consisting of two serine, leucine and 3-
hydroxy acid residues. In icosalide A1 (1), one of the leucine
residues is D-congured, whereas all of the amino acid residues
in icosalides A2 (2) and B (3) are L-congured. Icosalides A1 (1)
and A2 (2) both contain one eight-carbon and one ten-carbon 3-
hydroxy acid residue, whereas icosalide B (3) contains two eight-
carbon 3-hydroxy acid residues. The incorporation of a D-leucine
residue into icosalide A1 (1) has a dramatic eﬀect on its bio-
logical activity. While icosalide A1 (1) is active against Strepto-
coccus pyogenes (MIC: 8–16 mg mL1), icosalides A2 (2) and B (3)
do not show any antibacterial activity but are cytotoxic towards
replicating MDCK cells (CC50: 5 mg mL
1).18
The compound with the molecular formula C36H64N4O10 was
puried using semi-preparative HPLC and its planar structure
was shown to be identical to that of icosalide A1 (1) using
a combination of 1H, 13C and HMBC NMR experiments (Fig. S3
and Table S1†). The absolute stereochemistry of the amino acid
residues in the puried compound was determined via sapon-
ication of the esters, followed by semi-preparative HPLC
purication and MS analysis of the resulting pair of 3-
hydroxyacyl-dipeptides, acid hydrolysis to liberate theChem. Sci.constituent amino acids, derivatisation using Marfey's reagent
and comparison with the corresponding L and D-congured
leucine and serine standards (Fig. S4 and S5†). This revealed
that the Leu-2 residue is D-congured, conrming the identity of
the metabolite produced by B. gladioli as icosalide A1 (1). The
production level of the compound with the molecular formula
C34H60N4O10 was too low to permit characterisation by NMR
spectroscopy (Fig. S6†), but it seems likely that this has the
same planar structure as icosalide B (3). The activity of puried
icosalide A1 (1) against several Gram-positive and Gram-
negative bacteria, including the ESKAPE panel of pathogens,
and Candida albicans was tested. Modest activity against E.
faecium (MIC: 16 mg mL1) was observed (Table S2†).
Inspection of putative specialised metabolite biosynthetic
gene clusters in the previously reported genome sequence of B.
gladioli BCC0238,7 identied a single 15 kb gene (icoA) on
chromosome 2 encoding a nonribosomal peptide synthetase
(NRPS) with the requisite module and domain organisation for
icosalide assembly (Fig. 1B). This NRPS contains four adenyla-
tion (A) domains, two of which are predicted to be specic for L-
leucine and two for L-serine20 (Table S3†). It also contains ve
condensation (C) domains and a thioesterase (TE) domain,
which together account for the four amide and two ester bond-
forming reactions required to assemble the lipopeptidiolide
structure of the icosalides21 (Fig. 2A). We identied icoA in the
genomes of several other B. gladioli isolates (BCC0252,
BCC1677, BCC1698 and BCC1720), all of which were shown to
produce icosalide A1 (1). In contrast, no icosalide A1 (1)
production was detected in B. gladioli BCC1713 (Fig. S7†), which
is lacking icoA. These data are consistent with the hypothesis
that the NRPS encoded by icoA is responsible for icosalide
biosynthesis. To verify this, we inactivated the icoA gene in B.
gladioli BCC0238 using insertional mutagenesis. UHPLC-ESI-Q-
TOF-MS analysis of extracts from the icoA mutant conrmed
that it is no longer able to produce icosalides (Fig. 1C).
Icosalide A1 (1) was originally isolated from extracts of an
Aureobasidium species fungus (strain MSX 59166), whereas
icosalides A2 (2) and B (3) were isolated from a second less well
characterized fungal species (MSX 74159).18 The data presented
above suggested that B. gladioli bacteria associated with these
fungi might be the true producers of the icosalides isolated
from them. To investigate this hypothesis, total DNA from the
originally reported icosalide A1 (1) producer, Aureobasidium sp.
MSX 59166, was screened by PCR for orthologues of icoA and the
bacterial housekeeping gene recA. In both cases, we obtained
amplimers of the expected size (Fig. S8†), conrming that
a bacterium, likely harbouring an icoA orthologue, is associated
with the fungus. Burkholderia species can be unambiguously
identied via phylogenetic comparison of their recA
sequences.22 Thus, we compared the sequence of the recA
amplimer with the sequences of recA genes from 25 represen-
tative Burkholderia species. This showed that the Aureobasidium-
associated bacterium is B. gladioli (Fig. 1D). Illumina
sequencing of the total DNA from the Aureobasidium sp. allowed
an approximately 1 Mb contiguous sequence of bacterial DNA,
encompassing the icoA orthologue, to be assembled (Fig. S9†).
Comparison of this contiguous sequence with theThis journal is © The Royal Society of Chemistry 2019
Fig. 1 Structures of the icosalides, identiﬁcation of the NRPS-encoding gene responsible for icosalide biosynthesis in B. gladioli BCC0238 and
phylogenetic comparison of the recA sequence ampliﬁed from total DNA of the Aureobasidium sp. originally reported to produce icosalide A1
with various Burkholderia species. (A) Structures of icosalides A1 (1), A2 (2) and B (3). (B) Schematic representation of the 500 kDa NRPS
encoded by the 15 kb icoA gene. Domain abbreviations are as follows: C, condensation; A, adenylation; PCP, peptidyl carrier protein; TE,
thioesterase. (C) Extracted ion chromatogram atm/z 713.46 0.02, corresponding to [M + H]+ for icosalide A1, from LC-MS analyses of extracts
of agar-grown cultures of B. gladioli BCC0238 (top) and B. gladioli BCC0238 UicoA, in which the NRPS-encoding gene has been disrupted
(bottom). (D). Phylogenetic comparison of the recA sequence ampliﬁed from the total DNA extract of Aureobasidium sp. MSX 59166 (labelled
‘icosalide producer’) with recA sequences from 24 representative Burkholderia species, showing that the fungus-associated bacterium clades
with Burkholderia gladioli. The scale bar indicates the number of substitutions per site.
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View Article Onlinecorresponding region of the B. gladioli BCC0238 genome
showed a high degree of synteny (Fig. S9†), conrming that the
Aureobasidium sp. harbours a B. gladioli strain containing an
icoA orthologue. Although a Gram-negative bacterium could be
isolated from the Aureobasidium sp., it quickly lost viability and
was not identiable.
Inspection of the structure of icosalide A1 (1) suggests it is
assembled via initial formation of 3-hydroxyoctanoyl-D-leucinyl-
L-serinyl and 3-hydroxydecanoyl-L-serinyl-L-leucinyl thioesters,
which are joined via a pair of ester linkages to form the lip-
opeptidiolide. To gain insight into the role played by each of the
ve C domains of IcoA in the biosynthesis of icosalide A1 (1), we
carried out phylogenetic analyses.23 These indicated that theThis journal is © The Royal Society of Chemistry 2019rst and fourth domains group with chain initiating (CI)
domains, which are typically located at the N-terminus of the
rst module in NRPSs responsible for lipopeptide biosynthesis
and initiate chain assembly via N-acylation of the amino acyl
thioester bound to the downstream PCP domain with a fatty acyl
thioester. The third and h C domains of IcoA belong to the
LCL group, which catalyse formation of a peptide bond between
L-congured amino acyl thioesters attached to the upstream
and downstream PCP domains. In contrast, the second C
domain of IcoA clusters with bifunctional epimerisation–
condensation (CE) domains, which catalyse epimerisation of the
a-carbon in the aminoacyl thioester attached to the upstream
PCP domain, followed by condensation of the resulting D-Chem. Sci.
Fig. 2 Proposed mechanism for assembly of icosalide A1 (1) by IcoA.
Domain and module organisation of the NRPS, showing the PCP-
bound thioester intermediates proposed to be formed by each
module. The CI domains initiate lipopeptide chain assembly by N-
acylating the aminoacyl thioesters attached to the downstream PCP
domains with 3-hydroxyacyl thioester intermediates in fatty acid
biosynthesis. Abbreviations are as follows: A, adenylation domain; CI,
chain initiating condensation domain; CE, bifunctional epimerisation–
condensation domain; LCL, condensation domain that catalyses
condensation of L-conﬁgured aminoacyl donor and acceptor
substrates; PCP, peptidyl carrier protein domain; TE, thioesterase
domain. The residues used to predict the substrate speciﬁcity of A-
domains are shown in Table S3†.
Chemical Science Edge Article
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View Article Onlinecongured intermediate with an L-aminoacyl thioester attached
to the downstream PCP domain. These C domain functional
assignments led us to propose that modules 1 and 2 of IcoA are
responsible for assembly of the 3-hydroxyoctanoyl-D-leucinyl-L-
serinyl thioester intermediate in icosalide A1 (1) biosynthesis
(Fig. 2). The CI domain appended to the N-terminus of module 1
initiates chain assembly via N-acylation of the L-leucinyl thio-
ester attached to the module 1 PCP domain with a 3-hydrox-
yoctanoyl thioester, likely donated by the primary metabolic
fatty acid synthase (FAS). The C-domain in module 2 then
catalyses epimerisation of the resulting N-acyl-leucinyl thio-
ester, followed by condensation with the L-serinyl thioester
attached to the module 2 PCP domain. Module 3 of IcoA is very
unusual, because it contains an LCL domain directly followed by
a CI domain. We hypothesize that the CI domain in this module
catalyses a second chain initiation event, resulting in N-acyla-
tion of the L-serinyl thioester attached to the downstream PCP
domain with a 3-hydroxydecanoyl group, again likely provided
by the primary metabolic FAS. The LCL domain then catalyses
acylation of the hydroxyl group in the resulting 3-hydrox-
ydecanoyl-L-serinyl thioester with the 3-hydroxyoctanoyl-D-leu-
cinyl-L-serinyl thioester attached to the module 2 PCP domain.Chem. Sci.Elongation of the resulting intermediate with the L-leucinyl
thioester attached to the PCP domain in module 4, catalysed by
the upstream LCL domain, followed by lactonisation catalysed
by the downstream TE domain, yields icosalide A1 (Fig. 2).
To the best of our knowledge, initiation of chain assembly by
an embedded CI domain like the one found in module 3 of IcoA
is without precedent in NRPS enzymology. We thus sought to
experimentally validate the proposed chain initiation reaction
in vitro by overproducing the CI-A-PCP tri-domain from module
3 of IcoA in E. coli. The resulting N-terminal His6 fusion protein,
was puried to homogeneity using immobilised metal-ion
aﬃnity chromatography and the hexahistidine tag was cleaved
using thrombin (Fig. S10†). ESI-Q-TOF-MS analysis showed that
the PCP domain of this protein had been partially converted to
the holo form by an E. coli phosphopantetheinyl transferase
(Fig. S10†). To fully convert the PCP domain into the holo form
we incubated the protein with puried recombiant Sfp,
a substrate tolerant phosphopantetheinyl transferase from B.
subtilis,24 and coenzyme A.
The holo-CI-A-PCP tri-domain was incubated with ATP, L-Ser
and 3R-congured 3-hydroxyoctanoyl or 3-hydroxydecanoyl-
panthetheine thioesters, which mimic the (3R)-3-hydrox-
yoctanoyl and (3R)-3-hydroxydecanoyl-ACP intermediates in
fatty acid biosynthesis proposed to be intercepted by the CI
domains in modules 1 and 3, respectively, of the NRPS. UHPLC-
ESI-Q-TOF-MS analysis of the CI-A-PCP tri-domain showedmass
shis consistent with the formation of serinyl, 3-
hydroxyoctanoyl-serinyl and 3-hydroxydecanoyl-serinyl PCP-
thioesters (Fig. 3). When the CI-A-PCP tri-domain was replaced
with a mutant containing an Ala residue in place of the active
site His residue in the CI domain, only trace amounts of prod-
ucts were formed (Fig. 3).
Icosalide A1 contains an N-((3R)-3-hydroxydecanoyl)-L-serine
residue.19 The module 3 CI domain is thus expected to accept 3-
hydroxydecanoyl thioesters in preference to 3-hydroxyoctanoyl
thioesters. To test this hypothesis, we incubated the holo-CI-A-
PCP tri-domain with ATP, L-Ser and equimolar mixture of the
3R-congured 3-hydroxyoctanoyl and 3-hydroxydecanoyl-
panthetheine thioesters. UHPLC-ESI-Q-TOF-MS analysis
showed that only the product resulting from condensation with
the 10-carbon thioester is formed (Fig. 3). The incorporation of
3-hydroxyoctanoyl-L-serinyl-L-leucine into icosalide A2 (2), the
major icosalide produced by the MSX 74159 fungus, suggests
that the NRPS responsible for assembly of this metabolite
contains an embedded CI domain with a preference for 8-
carbon thioesters. It would therefore be interesting to investi-
gate the mechanisms underlying icosalide A2 biosynthesis.
The module 3 CI domain might also be expected to prefer R-
congured 3-hydroxyacyl thioesters to their S-congured coun-
terparts. (Note, however, that the ketoreductase in bacterial
fatty acid biosynthesis produces exclusively 3R-congured 3-
hydroxyacyl-ACP thioester intermediates.25 There may therefore
be no selective pressure to drive the evolution of stereo-
selectivity in CI domains.) To investigate whether the module 3
CI domain is stereoselective, we incubated the holo-CI-A-PCP tri-
domain with ATP, L-Ser and (3S)-3-hydroxyoctanoyl or (3S)-3-
hydroxydecanoyl-panthetheine thioesters. Although theThis journal is © The Royal Society of Chemistry 2019
Fig. 3 In vitro reconstitution of aminoacyl thioester formation andN-acylation by the CI-A-PCP tridomain frommodule 3 of IcoA. Deconvoluted
mass spectra of IcoA module 3 CI-A-PCP tri-domain. (A) Resulting from incubation with ATP, L-Ser and (3R)-3-hydroxyoctanoyl (top), (3R)-3-
hydroxydecanoyl (middle), or (3R)-3-hydroxyoctanoyl and (3R)-3-hydroxydecanoyl (bottom) pantetheine thioesters. (B) Following incubation
with ATP, L-Ser and (3S)-3-hydroxyoctanoyl (top), or (3S)-3-hydroxydecanoyl (bottom) pantetheine thioesters. (C) Resulting from incubation of
the H164A mutant with ATP, L-Ser and (3R)-3-hydroxyoctanoyl (top), or (3R)-3-hydroxydecanoyl (bottom) pantetheine thioesters. Dashed lines
indicate the peaks corresponding to each condensed species, and the holo- and L-Ser-loaded species are labelled as indicated in the bottom
right corner. Loading of L-Ser onto the PCP domain results in an 87 Damass increase. For the wild type IcoA CI-A-PCP tri-domain,N-acylation of
the serinyl-PCP thioester with the (3R)-3-hydroxyoctanoyl and (3R)-3-hydroxydecanoyl thioesters resulted in additional 142 and 170 Da mass
increases, respectively. Analogous mass increases were observed when the (3S)-3-hydroxyoctanoyl and (3S)-3-hydroxydecanoyl thioesters
were used, but the levels of product formation were lower, indicating that the CI domain prefers R-conﬁgured 3-hydroxyacyl thioesters. A small
amount of product formation was observed when the H164Amutant of the IcoA CI-A-PCP tri-domain was used in place of the wild type protein,
due to uncatalysed N-acylation of the serinyl thioester with the (3R)-3-hydroxyoctanoyl and (3R)-3-hydroxydecanoyl thioesters.
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View Article Onlinereaction with the 10-carbon thioester resulted in a signicant
degree of product formation, it was clearly less eﬃcient than the
reaction with the corresponding 3R-congured thioester (Fig.
3). In contrast, only trace amounts of product were formed in
the reaction employing the eight-carbon thioester (Fig. 3). Thus,
the CI domain appears to possess a moderate to high degree of
stereoselectivity, depending on the carbon chain length of the
substrate. Overall, our data show that the module 3 CI domain
of IcoA plays a key role in initiating the assembly of the (3R)-3-
hydroxydecanoyl-L-serinyl-L-leucinyl moiety of icosalide A1.
Conclusions
We have shown that the “fungal” antibiotic icosalide A1 (1),
originally isolated from an Aureobasidium sp., is produced by a B.
gladioli strain closely associated with the fungus. In addition, we
have shown that B. gladioli isolates from a range of sources,This journal is © The Royal Society of Chemistry 2019including CF lung infections, mushroom rot and insects also
produce this metabolite. Comparative genome sequence analysis
coupled with genetic manipulation allowed identication of
a gene encoding the NRPS responsible for icosalide A1 biosyn-
thesis. The third module of this NRPS has a very unusual archi-
tecture, containing a putative chain-initiating CI domain in
addition to a chain elongating LCL domain. Intact protein mass
spectrometry showed that this CI domain catalyses selective N-
acylation of a serinyl thioester bound to the module 3 PCP
domain with a (3R)-3-hydroxydecanoyl thioester. Thus, the
asymmetric lipopeptidiolide core of icosalide A1 (1) is assembled
by a unique mechanism involving two distinct chain initiation
events on a single NRPS subunit.
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